Ralf Reiners

Clinical Operations | @BicaraTx

[VJ Oncology @VJOncology]

🎥@YilmazMDPhD of @ClevelandClinic highlights promising results of BCA101 with pembrolizumab in recurrent, metastatic HNSCC. Manageable toxicities and better responses in HPV-negative patients:

➡️ https://t.co/Re7TKiK67K⬅️

#ASCO23 #HNCSM #ImmunoOnc

[Bicara Therapeutics @BicaraTx]

We're thrilled to welcome David Raben, M.D., to Bicara as CMO! Dr. Raben's more than 25 years of biopharma and academic translational #oncology comes at the right time as we continue to execute in the clinic and enter our next phase of growth. https://t.co/Fv1ijwa9gB

[Dana-Farber News @DanaFarberNews]

Encouraging anti-tumor activity for patients w/metastatic head & neck squamous cell carcinoma who are HPV-negative and treated with bifunctional EGFR/TGFβ inhibitor BCA101 w/pembrolizumab. Dose expansion results reported by @DanaFarber's Glenn Hanna, MD, (@HeadNeckMD) at #ASCO23.

[Bicara Therapeutics @BicaraTx]

Today at the #ASCO23 Annual Meeting Dr. Glenn Hanna presents exciting interim data from Bicara’s open-label Phase 1/1b dose expansion study of BCA101, demonstrating clinically meaningful activity among front-line R/M HNSCC. #headandneckcancer
https://t.co/QuOCHqEbk5

[Bicara Therapeutics @BicaraTx]

Announcing the upcoming oral presentation at #ASCO23 of dose expansion data in #headandneckcancer from the Phase 1/1b study of Bicara's lead candidate #BCA101. #CancerResearch #targetedtherapy #collaboration

https://t.co/PUgQPWr2tW

[Bicara Therapeutics @BicaraTx]

Today, Bicara’s lead #clinicaloperations team members, @dabohr and @ralf_reiners head to Lisbon, Portugal to attend #ECHNO2023 & meet with leading experts in #headandneckoncology from 3/9-3/11 on our #BCA101 #clinicaltrial #ECHNO2023 #ECHNO
https://t.co/skHMcHBRE6

[Bicara Therapeutics @BicaraTx]

We are so thrilled to announce a $108M Series B financing to advance our clinical-stage pipeline to treat cancer. We’re grateful for the hard work of our team & the support of co-lead investors #RedTreeVentureCapital & #RACapital & our other of investors. https://t.co/G0K2AhsIHT

[Bicara Therapeutics @BicaraTx]

We’re looking forward to presenting preclinical data on BCA356, a precision immunocytokine, at the Society for Immunotherapy of Cancer (SITC) Annual Meeting this week in Boston. @sitcancer For more info: https://t.co/PqoPKkM9Io

[Bicara Therapeutics @BicaraTx]

We recently hosted a webinar to discuss new data from the ongoing Phase 1/1b clinical trial of BCA101, our lead first-in-class biofunctional program. View the webinar: https://t.co/zESVJmHNE2

[Bicara Therapeutics @BicaraTx]

New data from the ongoing Phase 1/1b trial of our lead program, BCA101, have been presented at the #ESMO2022 annual congress. More details here: https://t.co/OOHd530mT4